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Abstract 
In Malta phenylketonuria (PKU) is mostly due 
to dihydropteridine reductase (DHPR) deficiency 
rather than phenylalanine hydroxylase deficiency 
(classical PKU), and is associated with long term 
neurodisability in all affected patients. The absence 
of newborn screening for PKU in Malta results in a 
later diagnosis and an increased burden on families 
and affected individuals. This burden is further 
compounded by problems in adherence to strict 
low-phenylalanine diets, in part due to problems 
dispensing appropriate amounts of low-
phenylalanine products and, in those with DHPR, 
the regular provision of neurotransmitter and 
cofactor supplementation. Over a 6.5-year review, 
complete provisions were dispensed in 68% of all 
prescriptions for L-dopa, 67% for 5-
hydroxytryptophan, 63% for low protein food, 61% 
for folinic acid and just 30% for low protein drinks. 
The problems encountered in the management of 
PKU highlight similar problems facing those with 
other rare, metabolic or ‘orphaned’ diseases. Yet 
some of these problems, particularly with regard to 
the dispensing of medicines and special food 
products can be reduced or eliminated. This would 
require a radical and comprehensive overhaul of the 
funding, procurement, stocking and dispensing of 
all pharmaceutical provisions in order to achieve 
stable phenylalanine levels throughout childhood 
and through to later life. 
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Introduction 
Phenylketonuria (PKU) is a rare condition 
affecting approximately 1 per 10-19,000 of most 
populations studied, and several subtypes exist.1-2 
The more uncommon atypical form resulting from 
dihydropteridine reductase (DHPR) deficiency2 
appears to be most prevalent in Malta, and it has 
been estimated that up to 3.3% of the population 
may carry the abnormal gene mutation for this 
condition.3 Despite this high carriage rate, 
phenylketonuria is not yet screened for at birth and 
presents late, although the case for routine newborn 
screening for PKU at a national level was made as 
early as 2005.4 The burden of PKU in childhood in 
Malta has been recently reviewed by Attard and 
Attard Montalto.5 The spectrum of PKU-related 
medical complications including significant 
neurodisability in all affected individuals, the daily 
requirements of medication and food alternatives, 
complex management and the psychosocial, 
educational and financial burden of PKU on 
patients, their families and Health services has been 
described in detail.5 
Five of the six children diagnosed with PKU 
in Malta since 1996 suffer with DHPR deficiency 
and, for them, dietary manipulation is insufficient 
and they require daily medication with dopamine-
pathway analogues and cofactors including L-
dopamine, 5-hydroxytryptophan, folinic acid as 
well as low protein food products and low or 
phenylalanine-free drinks/milk.6-7 The short half-
life of these medications necessitate dosing four to 
five times daily and delays in treatment of just a 
few hours is rapidly followed by neurological 
symptoms such as dystonia, irritability and 
behavioural changes.7 The requirement for regular 
and timely medication to sustain steady-state 
conditions is paramount and poses yet another 
challenge to the day-to-day burden of PKU.8 Ideal 
medical control can only be achieved by patient and 
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parent cooperation together with an efficient 
provision of all therapeutic requirements. The latter 
cannot be under-estimated and this study, a 
qualitative phenomenological case-based review of 
patient experiences, was designed to review this 
crucial aspect in the management of these children. 
 
Methods 
All children below the age of 16 years with 
any form of PKU were identified over a twenty-
year period, from 1996-2015. For those still 
resident in Malta in 2015, their official ‘yellow’ 
pharmacy-issued and updated cards were analysed 
for the preceding six and a half-year period, when 
Paediatric Services migrated to the new national 
hospital. All PKU-related prescriptions including 
medicines, food products and special milks/drinks, 
were identified and assessed for quantity dispensed. 
Routinely, and in accordance with the prevailing 
hospital policy at the time, these medications and 
provisions were supplied and dispensed for a two-
month period. Hence, any dispensed medication 
that provided adequate provisions for the next two 
months was taken to represent 100% for that 
individual prescription. Anything less (or more) 
was calculated as a percentage of the ‘standard’ 
two-month allowance, and this exercise was 
performed for all PKU prescriptions over the 6.5-
year period, January 2009 - June 2015. 
 
Results 
Over a twenty-year period from 1996-2015, 
five patients with PKU due to DHPR and one 
patient with classical PKU due to phenylalanine 
hydroxylase deficiency were diagnosed in Maltese 
children. Of these, three siblings with DHPR 
deficiency emigrated and prescriptions were 
analysed for the remaining three patients. Two boys 
with DHPR deficiency required regular medication 
with L-dopamine, 5-hydroxytryptophan and folinic 
acid, whilst both patients required low protein food 
and low/free phenylalanine milk/protein drink 
substitutes. The third patient with classical PKU 
was diagnosed midway through the study period 
and required low protein food and low/free 
phenylalanine milk but no dopamine pathway 
analogues. This study showed that, over a 6.5-year 
period, 456 prescriptions were issued for PKU-
related products. Of those, 412 were for the two 
patients with DHPR deficiency, with just 9.5% for 
milk and food products for the girl with classical 
PKU. If all prescriptions that were issued covered 
100% of the patients’ requirements in all cases, 
there should have been approximately 430 item-
prescriptions for these three patients in the same 
time period, averaging 30 each per annum (p.a.) for 
those with DHPR, and 12p.a. for classical PKU. In 
practice, DHPR patients were issued with 31.7 
prescriptions p.a. (median 31, SD±5.1), and one 
patient with classical PKU received 12.3 
prescriptions p.a. (median 12, SD±0.5). Table 1 
shows the breakdown of the individual 
prescriptions, and confirms that the main 
contributor to the 5.8 % ‘above estimate’ 
prescriptions arose due to repeat/extra prescriptions 
for low protein drinks.  
 
Table 1: Prescriptions according to pharmaceutical 
item over 6.5 years 
Prescripted item Estimated 
number of 
prescriptions 
Actual 
number of 
prescriptions 
L-dopamine 78 56 
5-hydroxytryptophan 78 80 
folinic acid 78 70 
Low protein food 78 84 
Low protein drinks* 98 130 
Phe-free protein milk** 20 36 
 
*Required for all patients; ** only for young girl 
with classical PKU, diagnosed half way through 
study period. 
 
The child with classical PKU did not require 
medication, was diagnosed more than half way 
during the study period and, for this patient, data 
was incomplete and was not included in subsequent 
analyses. For the two boys with DHPR, further 
breakdown of the actual amounts dispensed 
compared with what was prescribed for a two-
month period, showed that all PKU medications 
were intermittently or frequently supplied in 
inadequate amounts. As shown in Figure 1, L-Dopa 
was insufficiently dispensed in 32% of 
prescriptions, 5-hydroxytryptophan 33%, folinic 
acid in 39%, low protein food in 37% and PKU 
cooler (low protein drink) in 70% of all 
prescriptions. Figures 2A-E show the spread of 
prescriptions for each individual item over a 6.5- 
year period, and highlight the frequency of 
incomplete amounts dispensed relative to the 
prescribed two-monthly supply. Suboptimal 
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dispensing averaged approximately one third of all 
prescriptions for most items, with low protein 
drinks being consistently unavailable in sufficient 
quantities and, therefore, not dispensed ‘in full’ for 
more than two thirds of the time. 
 
 
 
Figure 1: Frequency (as %) of complete PKU items dispensed over 6.5 years 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2A: L-dopa 
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Figure 2B: 5HT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2C: Folinic acid 
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Figure 2D: PKU Cooler 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2E: Low protein food 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend to Figures 2A-E: Prescriptions are denoted as a percentage of the amount ordered where 100% equals 
stock dispensed for a two month period. Amounts issued as a % of the totals ordered are shown for 5 items over 
6.5 years, 2009-15. All items are frequently supplied in insufficient quantities: L-dopa 68%; 5HT 67%; low 
protein food (e.g. bread, pasta) 63%; folinic acid 61%, and low protein drinks (PKU cooler) being the most 
affected, averaging just 30% of the requested stock being dispensed. 
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Discussion 
Phenylketonuria (PKU) in Malta is mostly due 
to dihydropteridine reductase (DHPR) deficiency, is 
not screened for at birth and presents late, 
invariably with developmental delay and 
neurodisability.5 The management of this condition 
is complex and patients/their families face many 
challenges on a daily basis.5-8 This study has shown 
that the burden of PKU in Malta is further 
compounded by non-adherence to PKU diets, in 
part, due to irregular provision of neurotransmitter 
and cofactor supplementation, as well as PKU-
specific food items. Collectively, these children 
only consume small amounts of specific food items 
that change from time to time, and are not widely 
available, thereby discouraging local 
pharmaceutical agents to maintain stocks. Limited 
stocks lead to under-dispensing that, at best, is as 
much as 32% for some less problematic 
medications like L-dopa but may be as high as 70% 
of what is required for other items like low protein 
drinks (e.g. PKU Cooler). In practice, patients with 
PKU are issued with close-to-the-expected number 
of prescriptions per year with the exception of low 
protein drinks. For the latter, many more 
prescriptions are issued, presumably to ‘make up’ 
repeated deficits in the incomplete amounts 
dispensed. However, chronic under-dispensing was 
observed for all drugs and food items for PKU-
related prescriptions, a situation that resulted in 
frequent hospital attendances to collect the shortfall. 
These extra hospital trips for repeat ‘top-ups’ are 
inconvenient but, more significantly, any delays in 
treatment are associated with increased symptoms 
as doses are missed and compliance with PKU-diet 
is suboptimal.  
These shortfalls are the result of several 
factors including, at times, poor supply by the 
importing agents, compounded by the short half-life 
of some of these products especially the food 
products, milk and low protein drinks, and is not 
helped by the relatively costly and small quantities 
required. An inefficient procurement process with 
cumbersome tendering, little in-built flexibility and 
perpetual budgetary limitations often results in 
frequent ‘out of stock’ events, with subsequent 
incomplete/delayed prescriptions necessitating 
urgent and costly top-ups. In addition, food items 
frequently surpass their sell-by-date when collected 
by patients who, in turn, shun these items that are 
then discarded. Wastage begets ever more barriers 
to future orders, incurs greater delays and creates a 
vicious cycle of negative supply. 
Although this study is based on a qualitative 
review of a small number of patients, and carried 
out by the same patients’ potentially biased caring 
physicians who may be equally frustrated with 
chronic under-dispensing for their patients, it 
nevertheless highlights a chronic problem for these 
patients and a significant lacuna in the service. This 
study would suggest that a comprehensive overhaul 
of the pharmaceutical provision for children with 
PKU with effective dietary and medicinal provision 
is essential. A serious exercise to address all of 
these issues is required, but one option whereby 
families are given a carefully monitored budget to 
procure and manage their own supplies is one 
model that can be applied for PKU and similar rare 
disorders that require multiple, ‘special’, hard-to-
obtain, expensive items with a short half-life.9-10 
This would have to be combined with greater 
efficiency at the point of delivery by importing 
agents as it would otherwise simply transfer an 
added burden from the hospital pharmacy to the 
patient. In line with ‘best practice’, all these patients 
are managed in conjunction with a tertiary centre11 
and, alternatively, supplies could be obtained 
directly from the shared care tertiary centre in the 
UK, again with due monitoring from both health 
services. This set-up may also prove to be more 
cost-effective as it would eliminate wastage relating 
to expired/unused/surplus items. In tandem, a 
dedicated section/sub-department within the 
hospital service could be responsible for all aspects 
of supplies for PKU and related disorders, and 
would be expected to work closely with a local 
dedicated dietetic service that can closely monitor 
food items, ‘sell by dates’, stocks and supply, as 
well as liaise regularly with the tertiary metabolic 
centre. 
 
Conclusion 
A small number of children with PKU require 
low phenylalanine food products with or without 
additional medications, and they should receive the 
required products at the right quantity and at the 
right time. Failure to do so results in neurological 
and behavioural symptoms in the short term and 
may compound neurodisability long term. This is an 
important issue that has ethical as well as 
potentially serious medico-legal implications.  
Despite strenuous efforts by all concerned, the 
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current system has repeatedly failed to provide 
adequate stocks, ensure in-date medications and 
avoid delays in the dispensing of PKU-related 
items. A comprehensive review of all aspects of the 
present set-up is required with urgency. 
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